Copyright
©The Author(s) 2019.
World J Diabetes. Feb 15, 2019; 10(2): 114-132
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Published online Feb 15, 2019. doi: 10.4239/wjd.v10.i2.114
Table 13 Change in homeostasis model assessment-estimated insulin resistance in individual studies
| Study | HOMA-IR | P value | P value between groups | ||
| Group | Baseline | Study completion | |||
| Ito et al[12] | Ipragliflozin | 5.2 (2.5) | 4.8 (5.5) | Non-significant | 0.401 |
| Pioglitazone | 5.7 (3.4) | 4.5 (2.7) | < 0.05 | ||
| Eriksson et al[14] | Placebo | 4.2 (2.4) | -0.2 (1.4)1 | - | - |
| Omega 3-CA | 5.4 (2.9) | +0.3 (2.4)1 | - | Non-significant2 | |
| Dapagliflozin | 4.3 (1.9) | -1.1 (1.4)1 | - | < 0.052 | |
| O + D | 4.4 (1.7) | -0.9 (1.6)1 | - | < 0.052 | |
| Seko et al[16] | SGLT-2 inhibitor | 4.5 (0.5) | 7.9 (2.3) | 0.955 | - |
| Sitagliptin | 4.4 (0.5) | 6.5 (0.8) | 0.163 | ||
- Citation: Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132
- URL: https://www.wjgnet.com/1948-9358/full/v10/i2/114.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i2.114